The Technical AnalystExchange: ASX Industry: Health Care Equipment & Services
Imagion Biosystems Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0740
America/New_York / 28 mar 2024 @ 00:50
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2.42 mill |
| EPS: | -0.430 |
| P/E: | -0.170 |
| Earnings Date: | Feb 29, 2024 |
| SharesOutstanding: | 32.65 mill |
| Avg Daily Volume: | 0.0443 mill |
| RATING 2024-03-28 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | n/a | n/a | n/a | |||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.170 | sector: PE 1.258 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.170 | industry: PE 54.21 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0670 - 0.0810 ( +/- 9.46%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0740 (0.00% ) |
| Volume | 0.0132 mill |
| Avg. Vol. | 0.0443 mill |
| % of Avg. Vol | 29.78 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IBX.AX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IBX.AX
Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis; and a joint development agreement with Global Cancer Technology, Inc. to develop GCT's novel nanoscintillator technology for the treatment of breast cancer. The company was incorporated in 2016 and is based in San Diego, California.